http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2705374-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05c79644bc3a5c817aa2b9fccbc10c09 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fe285ab8a688f7caabfb5a0e44e8f86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc65cde3bf86f4b5ce549a57622eba3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22b07e4b8a102d366e76cbcc728754ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6c475238987ddcf41e61799af5729bf |
publicationDate | 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2705374-C1 |
titleOfInvention | Method for predicting the effectiveness of the treatment of moderate preeclampsia |
abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to obstetrics and can be used for prediction of clinical effectiveness of preeclampsia of moderate severity in pregnant women in gestation period of 24–37 weeks, including in patients with chronic arterial hypertension. That is ensured by determining the relative CCR2+ cell count in the neutrophil population before the initiation of the therapy in the pregnant women at the gestation period of 24–37 weeks, and measuring the average arterial pressure. If the relative CCR2+ cell count is less than or equal to 38.8 % and the average arterial pressure is less than or equal to 110 mm Hg, a positive effect of treating moderate preeclampsia is predicted, including in females with CAG. If the relative content of CCR2+ cells is more than 38.8 % and the average arterial pressure is more than 110 mm Hg, the absence of therapeutic effect is predicted.EFFECT: use of the given method enables predicting the effectiveness of the moderate-to-severe preeclampsia therapy, including in pregnant women with chronic arterial hypertension, which is necessary to apply a personified management approach in this category of patients, which will improve perinatal outcomes.1 cl, 5 ex, 1 tbl |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2752715-C1 |
priorityDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 914.